Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine‐resistant FMF patients
Pediatrics International · 2026-01 · 68 (1)
DOI: 10.1111/ped.70365 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pediatrics International, online erschienen am 04.03.2026. Verfasst von Pınar Akyüz Dağlı und 9 weiteren Autor:innen. Beteiligte Einrichtung: Ankara Bilkent City Hospital, Clinic of Rheumatology, Ankara, Turkey. Hauptthemen laut MEDLINE: Colchicine, Familial Mediterranean Fever, Biological Products, Drug Resistance. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background
Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disorder characterized by recurrent febrile episodes and serositis. Colchicine‐resistant FMF represents a challenging subset of patients with more severe clinical manifestations, limited treatment options, and increased risk of long‐term complications.
Objectives
This study aimed to compare clinical manifestations, genetic mutations, comorbidities, and treatment approaches between pediatric and adult patients diagnosed with colchicine‐resistant FMF.
Methods
This retrospective cross‐sectional study included 107 colchicine‐resistant FMF patients who received biologic treatment at Ankara Bilkent City Hospital between 2018 and 2023. Demographic, clinical, and genetic data were collected and compared between the groups. Treatment response was evaluated using the International Severity Score for FMF (ISSF).
Results
A total of 107 patients with colchicine‐resistant FMF were included, comprising 38 pediatric and 69 adult individuals. Female predominance was noted in both groups, more prominently in pediatric patients (68.4% vs. 53.6%). Classical FMF symptoms; abdominal pain (100% vs. 89.9%, p = 0.042), fever (97.4% vs. 82.6%, p = 0.025), chest pain (57.9% vs. 24.6%, p = 0.001), and arthritis (50.0% vs. 26.1%, p = 0.013) were significantly more prevalent in pediatric patients. In contrast, adult patients more frequently presented with inflammatory back pain (40.6% vs. 10.5%, p = 0.001), persistent inflammation (24.6% vs. 7.9%, p = 0.039), and amyloidosis (36.2% vs. 2.6%, p = 0.001). Following biological treatment, median ISSF scores decreased significantly in both groups (5.0 to 0.0, p < 0.001). Although overall MEFV mutation distribution was similar between groups ( p = 0.574).
Conclusion
This study highlights significant age‐related differences in clinical presentation and treatment patterns among crFMF patients. Pediatric cases tend to present with a more typical and severe phenotype, while adults exhibit higher rates of complications such as amyloidosis. These findings underscore the need for age‐tailored diagnostic and therapeutic approaches in colchicine‐resistant FMF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ankara Bilkent City Hospital, Clinic of Rheumatology, Ankara, Turkey.
- Department of Pediatrics, Division of Pediatric Rheumatology, Ankara Bilkent City Hospital, University of Health Sciences, Ankara, Turkey.
- Aksaray Education and Research Hospital, Clinic of Rheumatology, Aksaray, Turkey.
- Şanlıurfa Training and Research Hospital, Clinic of Rheumatology, Şanlıurfa, Turkey.
- Ankara Gaziler Physical Therapy and Rehabilitation Training and Research Hospital, Clinic of Rheumatology, Ankara, Turkey.
- Department of Internal Medicine, Division of Rheumatology, Ankara Bilkent City Hospital, Ankara Yıldırım Beyazıt University, Ankara, Turkey.
ORCID-Profile: Pınar Akyüz Dağlı, Mehveş Işiklar Ekici, Ahmet Kor
Zitieren
APA
Akyüz Dağlı, P., Konak, H. E., Soytürk, G., Işiklar Ekici, M., Kor, A., Polat, B., Akif Eksin, M., Babaoğlu, H., Çelikel Acar, B., & Erten, Ş. (2026). Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine‐resistant FMF patients. Pediatrics International, 68(1). https://doi.org/10.1111/ped.70365
Vancouver
Akyüz Dağlı P, Konak HE, Soytürk G, Işiklar Ekici M, Kor A, Polat B, et al. Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine‐resistant FMF patients. Pediatrics International. 2026;68(1). doi:10.1111/ped.70365
BibTeX
@article{AkyzDal2026,
author = {Akyüz Dağlı, Pınar and Konak, Hatice Ecem and Soytürk, Gülşah and Işiklar Ekici, Mehveş and Kor, Ahmet and Polat, Bünyamin and Akif Eksin, Mehmet and Babaoğlu, Hakan and Çelikel Acar, Banu and Erten, Şükran},
title = {Clinical, genetic, and therapeutic differences in pediatric versus adult colchicine‐resistant FMF patients},
journal = {Pediatrics International},
year = {2026},
volume = {68},
number = {1},
doi = {10.1111/ped.70365}
}
EUVIMED